Last updated 13 days ago
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
825 patients around the world
Available in Puerto Rico, Argentina, United States
Ocular Therapeutix, Inc.
5Research sites
825Patients around the world
This study is for people with
Macular Degeneration
Age-related Macular Degeneration
Requirements for the patient
From 50 Years
All Gender
Medical requirements
- Treatment naïve juxtafoveal and/or SFNV secondary to Neovascular Age-Related Macular Degeneration (nAMD) with leakage involving the fovea in the study eye prior to Screening, or have a diagnosis of Neovascular Age-Related Macular Degeneration (nAMD) in study eye within 3 months prior to screening and received up to 2 monthly injections of 2 mg aflibercept with last injection approximately 4 weeks prior to Screening.Have provided written consent.
- Monocular subject or Best Corrected Visual Acuity (BCVA) score of <20 ETDRS letters or 20/400 in fellow eye at Screening.Have evidence of a scar, fibrosis, or atrophy of >50% of the total lesion in the study eye.
Sites
Organización Médica de Investigación (OMI)
Recruiting
Fundación Zambrano
Recruiting
Centro Oftalmológico Dr. Daniel Charles
Recruiting
Oftar Mendoza - Capital
Recruiting
Emanuelli Research and Development Center LLC
Recruiting
SponsorOcular Therapeutix, Inc.
Study typeInterventional
Conditions
Age-related Macular Degeneration
Requirements
From 50 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06495918
